The goal of this study is to understand how the protein CD81 affects myeloid leukemia (especially AML) and whether it can help predict patient outcomes or guide treatment.
The main question it aims to answer:
Is high CD81 expression in myeloid leukemia cells linked to more aggressive disease, poorer treatment response, or shorter survival in patients?
Participants:
* Newly diagnosed myeloid leukemia patients (primary focus on AML)
* Bone marrow or blood samples will be collected during routine diagnostic procedures